These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30261917)

  • 1. Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY).
    Finger E; Berry S; Cummings J; Coleman K; Hsiung R; Feldman HH; Boxer A
    Alzheimers Res Ther; 2018 Sep; 10(1):102. PubMed ID: 30261917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of oxytocin on social cognition and behaviour in frontotemporal dementia.
    Jesso S; Morlog D; Ross S; Pell MD; Pasternak SH; Mitchell DG; Kertesz A; Finger EC
    Brain; 2011 Sep; 134(Pt 9):2493-501. PubMed ID: 21859765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability.
    Finger EC; MacKinley J; Blair M; Oliver LD; Jesso S; Tartaglia MC; Borrie M; Wells J; Dziobek I; Pasternak S; Mitchell DG; Rankin K; Kertesz A; Boxer A
    Neurology; 2015 Jan; 84(2):174-81. PubMed ID: 25503617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for a placebo-controlled, within-participants crossover trial evaluating the efficacy of intranasal oxytocin to improve pain and function among women with chronic pelvic musculoskeletal pain.
    Rash JA; Toivonen K; Robert M; Nasr-Esfahani M; Jarrell JF; Campbell TS
    BMJ Open; 2017 Apr; 7(4):e014909. PubMed ID: 28416501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neural effects of oxytocin and mimicry in frontotemporal dementia: A randomized crossover study.
    Oliver LD; Stewart C; Coleman K; Kryklywy JH; Bartha R; Mitchell DGV; Finger EC
    Neurology; 2020 Nov; 95(19):e2635-e2647. PubMed ID: 32963103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Oxytocin in Social Circuits and Social Behavior in Dementia.
    Piguet O; Ahmed RM; Kumfor F
    Methods Mol Biol; 2022; 2384():67-80. PubMed ID: 34550569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fair play: social norm compliance failures in behavioural variant frontotemporal dementia.
    O'Callaghan C; Bertoux M; Irish M; Shine JM; Wong S; Spiliopoulos L; Hodges JR; Hornberger M
    Brain; 2016 Jan; 139(Pt 1):204-16. PubMed ID: 26503957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promising effects of oxytocin on social and food-related behaviour in young children with Prader-Willi syndrome: a randomized, double-blind, controlled crossover trial.
    Kuppens RJ; Donze SH; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2016 Dec; 85(6):979-987. PubMed ID: 27486141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy for Neuropsychiatric Symptoms in Frontotemporal Dementia.
    Le C; Finger E
    CNS Drugs; 2021 Oct; 35(10):1081-1096. PubMed ID: 34426949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New potential therapeutic approaches in frontotemporal dementia: oxytocin, vasopressin, and social cognition.
    Finger EC
    J Mol Neurosci; 2011 Nov; 45(3):696-701. PubMed ID: 21618004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. White matter disease contributes to apathy and disinhibition in behavioral variant frontotemporal dementia.
    Powers JP; Massimo L; McMillan CT; Yushkevich PA; Zhang H; Gee JC; Grossman M
    Cogn Behav Neurol; 2014 Dec; 27(4):206-14. PubMed ID: 25539040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial.
    Scherer RW; Drye L; Mintzer J; Lanctôt K; Rosenberg P; Herrmann N; Padala P; Brawman-Mintzer O; Burke W; Craft S; Lerner AJ; Levey A; Porsteinsson A; van Dyck CH;
    Trials; 2018 Jan; 19(1):46. PubMed ID: 29347996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose intranasal oxytocin delivered with Breath Powered device dampens amygdala response to emotional stimuli: A peripheral effect-controlled within-subjects randomized dose-response fMRI trial.
    Quintana DS; Westlye LT; Alnæs D; Rustan ØG; Kaufmann T; Smerud KT; Mahmoud RA; Djupesland PG; Andreassen OA
    Psychoneuroendocrinology; 2016 Jul; 69():180-8. PubMed ID: 27107209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia.
    Vivash L; Malpas CB; Churilov L; Walterfang M; Brodtmann A; Piguet O; Ahmed RM; Bush AI; Hovens CM; Kalincik T; Darby D; Velakoulis D; O'Brien TJ
    BMJ Open; 2020 Nov; 10(11):e040100. PubMed ID: 33199422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Apathy in frontotemporal dementia and Alzheimer's disease: are there distinct profiles?].
    Derouesné C; Lacomblez L; Fiori N; Gély-Nargeot MC; Bungener C
    Geriatr Psychol Neuropsychiatr Vieil; 2012 Mar; 10(1):107-15. PubMed ID: 22414405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial.
    Yatawara CJ; Einfeld SL; Hickie IB; Davenport TA; Guastella AJ
    Mol Psychiatry; 2016 Sep; 21(9):1225-31. PubMed ID: 26503762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in adults with autism spectrum disorder: a randomized placebo-controlled double-blind crossover trial.
    Quintana DS; Westlye LT; Hope S; Nærland T; Elvsåshagen T; Dørum E; Rustan Ø; Valstad M; Rezvaya L; Lishaugen H; Stensønes E; Yaqub S; Smerud KT; Mahmoud RA; Djupesland PG; Andreassen OA
    Transl Psychiatry; 2017 May; 7(5):e1136. PubMed ID: 28534875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Pharmacological Interventions for Symptoms of Behavioral Variant Frontotemporal Dementia: A Systematic Review.
    Trieu C; Gossink F; Stek ML; Scheltens P; Pijnenburg YAL; Dols A
    Cogn Behav Neurol; 2020 Mar; 33(1):1-15. PubMed ID: 32132398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic importance of apathy in syndromes associated with frontotemporal lobar degeneration.
    Lansdall CJ; Coyle-Gilchrist ITS; Vázquez Rodríguez P; Wilcox A; Wehmann E; Robbins TW; Rowe JB
    Neurology; 2019 Apr; 92(14):e1547-e1557. PubMed ID: 30842292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal oxytocin in the treatment of autism spectrum disorders: a review of literature and early safety and efficacy data in youth.
    Anagnostou E; Soorya L; Brian J; Dupuis A; Mankad D; Smile S; Jacob S
    Brain Res; 2014 Sep; 1580():188-98. PubMed ID: 24508578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.